When Is a Cystoscopy Really Necessary?

Cystoscopy is genuinely necessary when a urologist needs a direct look inside your bladder or urethra to evaluate blood in your urine, monitor a known bladder cancer, investigate an unexplained blockage, or remove a foreign body. Outside those core scenarios, the procedure is performed more often than the evidence supports. Research on recurrent urinary tract infections, low-risk microscopic blood in the urine, and certain surveillance schedules after cancer treatment all suggest that many patients undergo cystoscopies that change nothing about their care. Knowing when the test is likely to find something actionable and when it is unlikely to help can make conversations with your urologist more productive.

Blood in the Urine Is the Most Common Reason

Visible blood in your urine, called gross hematuria, is the single clearest reason for a cystoscopy. The concern is bladder cancer, and cystoscopy remains the most sensitive tool for finding it. In a study of 778 patients at a hematuria clinic, flexible cystoscopy had a sensitivity of about 98% for diagnosing bladder cancer, compared with roughly 95% for CT urography used as a standalone replacement test.¹ That small edge matters when the stakes are a missed cancer, which is why guidelines consistently recommend cystoscopy for anyone presenting with unexplained visible blood.

When the initial workup is negative but gross hematuria comes back, the question gets murkier. A study following over 1,300 patients who had an initial negative evaluation found that about 18% experienced recurrent visible blood over a median follow-up of six years. Among those patients, cancer was found in a small number: six bladder cancers, two prostate cancers, and one kidney cancer.² Those numbers are low in percentage terms, but because the cancers found were sometimes aggressive, repeating the workup for recurrent visible hematuria still makes clinical sense for most patients.

Microscopic Hematuria Depends on Your Risk Profile

Microscopic hematuria, meaning red blood cells found on a urine test but invisible to the naked eye, is far more common and far less likely to signal cancer. The American Urological Association updated its guidelines to sort patients into low, intermediate, and high risk for malignancy based on factors like age, sex, smoking history, and how many red blood cells appear on the test.³ For low-risk patients, the guidelines recommend repeating the urine test in six months rather than jumping straight to cystoscopy. Intermediate-risk patients are offered cystoscopy with shared decision-making. High-risk patients are recommended to get one.

A 2025 validation study tested this risk system and found that it works reasonably well for predicting bladder and other urothelial cancers. High-risk patients had a urothelial cancer rate of about 3.8%, compared with 0.8% in the intermediate group and just 0.2% in the low-risk group.⁴ The key predictors were age, male sex, smoking pack-years, and the number of red blood cells in the urine. In practical terms, a 35-year-old nonsmoking woman with a trace of blood on one urine test has very different odds than a 65-year-old man with a 30-pack-year smoking history and persistently abnormal results. Cystoscopy is far more justified in the latter case.

A meta-analysis looking specifically at diagnostic yield confirmed this pattern: the pooled bladder cancer detection rate from cystoscopy in microhematuria patients was about 2.7% overall, but nearly doubled to roughly 4.6% in higher-risk groups.⁵ If you are in the low-risk category, the chance of cystoscopy finding cancer is very small, and the guideline-supported approach of monitoring with repeat urine tests is reasonable.

Bladder Cancer Surveillance Is Where Cystoscopy Adds Up

Once someone has been diagnosed with non-muscle-invasive bladder cancer and had the tumor removed, surveillance cystoscopy becomes a regular part of life. This is the scenario where the procedure is most clearly necessary over an extended period, because bladder cancer has one of the highest recurrence rates of any malignancy. In a study of 51 low-risk patients, about 80% of recurrences showed up within the first two years.⁶ That high recurrence rate is why surveillance protocols call for repeated procedures, but the ideal frequency depends on risk.

For intermediate-risk bladder cancer, research suggests that checking every six months rather than every three months catches recurrences in a timely way without the added cost and discomfort of more frequent visits.⁷ A systematic review found that the first cystoscopy after tumor removal should happen within three to four months, since delaying it raises recurrence and progression risk. For low-risk patients who stay recurrence-free, some evidence supports stopping surveillance after five years, though patients with additional risk factors like active smoking may benefit from continued monitoring.⁸ For high-risk patients, there is no clear evidence that any particular schedule reduces mortality better than another, meaning the aggressive protocols many patients are on may include more cystoscopies than strictly needed.

Recurrent UTIs Rarely Need a Scope

One of the more common scenarios where cystoscopy is ordered but rarely changes management is recurrent urinary tract infections in women. When imaging is normal and there are no red-flag symptoms, the chance of finding something meaningful on cystoscopy is low. In a study of 110 women with recurrent UTIs, only about 8% had significant findings at cystoscopy, most of which were urethral strictures. When prior imaging was normal, the negative predictive value was 99%, meaning a normal imaging result almost perfectly predicted a normal cystoscopy.⁹

A larger comparison study reinforced this. Across two hospital sites, researchers found that routine cystoscopy in women with recurrent UTIs turned up abnormalities in only a small number of patients, and the findings rarely altered treatment plans. The authors concluded that routine cystoscopy and ultrasound in this population should not be standard practice because they yield few abnormalities and drive up costs.¹⁰ If your urologist recommends cystoscopy for recurrent UTIs and your imaging has been clean, it is worth asking what specific finding they are hoping to rule out. In some cases, such as a suspected fistula or structural abnormality that did not show on imaging, the procedure is justified. In routine recurrent infections without complications, the evidence is thin.

Voiding Problems and Urethral Strictures

When someone develops trouble urinating, including a weak stream, straining, or incomplete emptying, cystoscopy can help identify or confirm a urethral stricture or other mechanical blockage. This is particularly relevant after prostate surgery. A study tracking patients after endoscopic prostate surgery found that all 23 patients who met criteria for post-operative cystoscopy were confirmed to have urethral strictures, with the most common location being the membranous urethra. The median time from surgery to stricture discovery was about four months.¹¹ In these cases, cystoscopy is both diagnostic and often therapeutic, since the stricture can sometimes be treated during the same procedure.

For people with lower urinary tract symptoms not explained by an obvious cause, a diagnostic cystoscopy may add information, but it is less clearly necessary than in the hematuria or cancer scenarios. The procedure is most useful here when noninvasive tests like flow measurements and ultrasound have already been done and the results do not explain the symptoms. Jumping straight to cystoscopy without trying those steps first is generally not recommended.

What the Procedure Actually Feels Like

A major reason patients worry about cystoscopy is the assumption that it will be painful. The reality depends heavily on whether a flexible or rigid scope is used, and whether you are male or female. In women, a study comparing the two approaches found that median discomfort scores were low for both flexible and rigid cystoscopy, with no statistically significant difference.¹² For women, the choice of scope type matters less to comfort.

In men, the difference is more pronounced. A multi-center study found that men undergoing flexible cystoscopy were pain-free about 59% of the time, compared with only 24% using rigid instruments. Mild and moderate pain were both significantly more common with rigid scopes.¹³ Flexible cystoscopy has largely become the standard for outpatient diagnostic use, particularly in men, for exactly this reason. If your urologist is scheduling a rigid cystoscopy in the office rather than flexible, it is reasonable to ask why.

For men who do undergo rigid cystoscopy, local anesthetic gel instilled into the urethra helps considerably, though how long it sits before the procedure matters. Research found that a 15-minute dwell time for lidocaine gel provided the best pain relief, with patients reporting mean pain scores that were roughly a third of those who had minimal dwell time.¹⁴ If your procedure is scheduled, you can ask the medical team to allow the gel adequate time before beginning.

Infection Risk and Antibiotics

The most commonly discussed risk of cystoscopy is urinary tract infection. Older data put the infection rate at around 7.5% for outpatient flexible cystoscopy.¹⁵ More recent studies using modern sterilization practices have found lower complication rates. One study comparing sterile single-use scopes with reprocessed high-level-disinfected ones found an overall urological complication rate of about 1.4%, with symptomatic UTI occurring in under 1% of patients.¹⁶

A common question is whether you need antibiotics before or after the procedure. Current guidelines from both European and American urology associations say no for uncomplicated cystoscopy in low-risk patients. A randomized trial confirmed that routine antibiotic prophylaxis after flexible cystoscopy can be safely skipped in patients without high-risk features.¹⁷ Even among bladder cancer patients with bacteria in their urine but no symptoms, antibiotics before outpatient cystoscopy do not appear necessary.¹⁸ If you are offered routine antibiotics before an uncomplicated diagnostic cystoscopy, the current evidence supports declining them, though patients with immunosuppression, joint replacements, or other risk factors should discuss their specific situation. A recent study of high-risk patients found bacteriuria rates around 9-10% regardless of whether antibiotics were given, with no cases of sepsis in either group.¹⁹

Blue-Light Cystoscopy and Enhanced Detection

Standard cystoscopy uses white light, which is effective at spotting raised, papillary tumors but can miss flat lesions like carcinoma in situ. Blue-light cystoscopy uses a photosensitizing agent that makes cancerous tissue glow under blue-violet light. The improvement in detection is substantial: a meta-analysis of nine trials found that blue-light cystoscopy detected about 41% more carcinoma in situ lesions and about 15% more papillary tumors compared with white light alone.²⁰ Data from a U.S. registry found that adding blue light to standard white-light cystoscopy pushed the overall sensitivity for any malignant lesion up to about 98.5%, compared with 76% for white light alone.²¹

Originally restricted to the operating room with rigid scopes, blue-light technology has gained expanded FDA approval for use with flexible office cystoscopes, which makes it available in routine surveillance. If you are undergoing cystoscopy specifically for bladder cancer surveillance, it is worth asking whether blue-light capability is available at your facility, as it may reduce the number of follow-up procedures needed if more lesions are caught early.

Can Imaging Replace Cystoscopy?

CT urography captures the kidneys, ureters, and bladder in one scan and is routinely used alongside cystoscopy for hematuria workups. While it is excellent for upper tract tumors, its performance for bladder lesions falls short of cystoscopy. CT virtual cystoscopy, which reconstructs a 3D view of the bladder interior from CT data, has shown promising accuracy in small studies, with one reporting sensitivity and specificity both around 92%.²² Another study found that CT virtual cystoscopy detected the same number of bladder lesions as conventional cystoscopy.²³

These results sound encouraging, but virtual cystoscopy cannot take a biopsy. If something suspicious is found, conventional cystoscopy is still needed for tissue sampling. And the numbers come from small studies at specialized centers. For routine clinical use, imaging has not replaced cystoscopy for bladder evaluation, though it complements it well for assessing the upper urinary tract. A cost-effectiveness analysis found that combining ultrasound with cystoscopy was the most economical diagnostic approach for microscopic hematuria, detecting nearly as many cancers as the CT-plus-cystoscopy combination at a fraction of the cost per additional cancer found.²⁴

Urinary Biomarkers Are Promising but Not There Yet

Several urine-based tests have received FDA approval for detecting bladder cancer, including NMP22, BTA, and UroVysion FISH. Newer genomic tests like AssureMDx and CxBladder have shown strong performance in studies and could theoretically reduce the need for surveillance cystoscopy, especially in patients at lower risk for recurrence. Despite the promise, no urinary biomarker has replaced cystoscopy in clinical practice due to inconsistent combinations of sensitivity, specificity, and cost-effectiveness.²⁵ These tests tend to perform well in research settings but less reliably in diverse real-world populations.²⁶

The practical implication for patients today is that if your urologist orders cystoscopy for cancer surveillance, a urine biomarker alone is not a reliable substitute. Some clinicians use biomarkers to help decide between borderline cases, such as whether a patient with microhematuria and low-risk features truly needs cystoscopy. But for the foreseeable future, the scope remains the gold standard.

Cystoscopy in Children

Pediatric cystoscopy occupies a different landscape. Bladder cancer is exceedingly rare in children, so the hematuria-to-cancer pathway that drives adult practice does not apply. Evidence going back decades has argued that cystoscopy is overused in pediatric patients and frequently provides no diagnostic or therapeutic benefit for common referral reasons like recurrent infections, bed-wetting, or blood in the urine.²⁷

Where cystoscopy is clearly valuable in children is for evaluating urinary obstruction, complex congenital anomalies, and foreign body retrieval. Children who swallow or insert small objects, particularly magnetic beads, may require cystoscopy both to confirm the location and to remove the object. A case series found that cystoscopy was the first-line method for both diagnosis and treatment in these situations, with successful retrieval and no postoperative complications.²⁸ For structural concerns like posterior urethral valves, cystoscopy is not just diagnostic but therapeutic, since the obstructing tissue can be incised during the same procedure.

How Cystoscopy Technology Has Evolved

The modern flexible cystoscope bears almost no resemblance to its ancestor. Early cystoscopy, dating to the early nineteenth century, relied on reflected candlelight and offered a dim, distorted view that was as unpleasant for the patient as it was unhelpful for the physician. The development of lenses, incandescent light, and eventually fiber optics transformed the tool from a crude instrument into the high-resolution digital device used today.²⁹ Modern video cystoscopes project the image onto a screen, which allows the patient to watch (if they are so inclined), the urologist to point out findings in real time, and trainees to learn without requiring a second scope insertion. The miniaturization of scopes has also improved comfort considerably, and single-use disposable cystoscopes are becoming more common, addressing concerns about reprocessing and infection control.